Review Article
Emerging Pharmacotherapies for Diabetic Macular Edema
Table 1
Selected clinical trials of corticosteroids in treatment of diabetic macular edema.
| Agent (no. patients) | Main outcomes | Reference |
| Intravitreal triamcinolone (693) | Less favorable outcomes versus photocoagulation at 24 and 36 months | [22, 23] | Peribulbar triamcinolone (109) | Less favorable outcomes versus intravitreal triamcinolone at 34 weeks | [28] | Fluocinolone acetonide implant (Retisert) (197) | Effective treatment of DME at 36 months, but high risks of cataract and glaucoma | [32] | Fluocinolone acetonide implant (Iluvien) (956) | Generally favorable results at 24 months | [34] | Dexamethasone drug delivery system (Ozurdex) (171) | Generally favorable results at 90 days | [36] |
|
|